HEV G Specific Neutra™ Antibody Products

Hendra Virus Glycoprotein G (HEV G) Specific Neutra™ Antibody Products: Accelerating Your Research and Development. Are you facing challenges in developing effective countermeasures against Hendra virus, a highly pathogenic zoonotic agent? Creative Biolabs' HEV G Specific Neutra™ Antibody Products provide a powerful solution to accelerate your research and development in this critical area.

Overview of HEV G

Human and horse populations along with other mammalian species face infection risks from the deadly paramyxovirus known as Hendra virus (HEV). When infected people develop severe respiratory and neurological diseases their mortality rates become high. Researchers first identified the virus in Australia during the year 1994. The Hendra virus glycoprotein G (HEV G) plays a central role in the infection mechanism.

Structure of HEV G

HEV G is a viral surface protein that plays a crucial role in the attachment of the virus to host cells. It is a type I transmembrane protein. The protein is essential for the virus to enter the host cell. The structure of HEV G has been studied, and specific domains have been identified that are responsible for receptor binding and membrane fusion.

Fig. 1 EV-D68 strategically targets key molecules within the TLR and RLR pathways to evade innate immune responses.^{1, 3}

Related Signaling Pathways

The HEV G protein enables viral entry through specific interactions with host cell receptors. These interactions lead to host cell signaling pathways activation which enables the viral membrane to merge with the host cell membrane so the virus can penetrate and start infection.

Application of Anti-HEV G Antibody

Monitoring Viral Evolution

Anti-HEV G antibodies play a critical role in creating serological tests like ELISAs which enable HEV infection detection. The assays enable monitoring and control of HEV outbreaks through the detection of infected animals. Scientists use anti-HEV G antibodies to create DIVA ELISA tests which distinguish between vaccinated animals and those with HEV infections. Accurate HEV population surveillance and management depends on this approach.

Fig. 2 The percent inhibition results from the HEV differentiating ELISA, distinguishing between negative, vaccinated, and positive (infected) equine groups, are presented for both the sG and N proteins.^{2, 3}

Therapeutic Strategies Exploitation

Therapeutic interventions for combating HEV infection can be developed using anti-HEV G antibodies. The antibodies have the ability to stop the virus from entering host cells, which leads to a reduction in disease severity. Studies demonstrate that monoclonal antibodies directed against HEV G provide effective protection to animals from HEV infection. The production of therapeutic antibodies serves as a vital tool in both treating and preventing severe diseases caused by Henipaviruses.

In Creative Biolabs, you can gain access to premium HEV G-specific Neutra™ Antibody Products, which support all your research and development activities. The design of our products helps researchers meet demanding scientific standards while ensuring reliable and reproducible outcomes.

REFERENCES

1. Steffen, Deborah L., et al. "Henipavirus mediated membrane fusion, virus entry and targeted therapeutics." Viruses 4.2 (2012): 280-309. https://doi.org/10.3390/v4020280
2. McNabb, Leanne, et al. "Development and Validation of a Differentiating Infected from Vaccinated Animals (DIVA) Enzyme-Linked Immunosorbent Assay (ELISA) Strategy for Distinguishing Between Hendra-Infected and Vaccinated Horses." Viruses 17.3 (2025): 354. https://doi.org/10.3390/v17030354
3. Distributed under Open Access license CC BY 4.0, without modification.